A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
Merck Sharp & Dohme LLC
Augusta University
Eli Lilly and Company
Baylor College of Medicine
Bayer
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Pfizer